Single Patient, Expanded Access. IND 162739,
Role: PI,
Status: Approved
For Profit Organization
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy,
Role: PI,
Otsuka Pharmaceuticals,
(05/2026 - 05/2027)
Status: Approved
Listening to Patients: Building a Patient-Centered Outcomes Agenda for IgA Nephropathy,
Role: PD/PI,
Otsuka Pharmaceuticals,
(12/2024 - 12/2026)
Status: Awarded
Building a Patient-Centered Outcomes Agenda for IgA Nephropathy,
Role: PI,
Otsuka Pharmaceuticals,
(03/2026)
Status: Approved
CYTB323J12201: A Phase 2, Open-label, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel in Patients Suffering with active, refractory Systemic Lupus Erythematosus (SLE) or Active, Refractory Lupus Nephritis (LN),
Role: PI,
Novartis Pharmaceuticals Corporation,
(07/2026 - 07/2027)
Status: Approved
A Phase 2/3, Multicenter, Open-label Trial to Evaluate the Long-term
Safety, Tolerability, and Efficacy of Sibeprenlimab Administered
Subcutaneously in Subjects with Immunoglobulin A Nephropathy,
Role: PI,
Otsuka Pharmaceuticals,
(03/2026 - 03/2027)
Status: Approved
A Phase 2, adaptive, randomized, open-label, assessor-blinded active-controlled study to evaluate the efficacy and safety of rapcabtagene autoleucel versus Standard of Care in patients suffering from systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN)
Novartis protocol - CYTB323J12201,
Role: PD/PI,
Novartis Pharmaceuticals Corporation,
(05/2025 - 12/2030)
Status: Awarded
Internal
Echocardiographic Features and Genotypic Variations in Autosomal Dominant Polycystic Kidney Disease,
Role: PI,
LLU Dept. of Medicine,
(06/2024)
Status: Approved
HRQOL in Patients with Lupus Nephritis and IgA Nephropathy,
Role: PI,
LLU Dept. of Medicine,
(12/2023)
Status: Approved
Evaluation of PKD diagnosis impact on the patients' quality of life,
Role: PI,
LLU Dept. of Medicine,
(11/2023)
Status: Approved
Distress Tolerance in Lupus Nephritis; Exploring the Impact of Acceptance on Disease Severity,
Role: PI,
LLU Dept. of Medicine,
(09/2023)
Status: Approved
Cardiovascular risk management in lupus nephritis and IgA nephropathy patients,
Role: PI,
LLU Dept. of Medicine,
(03/2023)
Status: Approved
A multi-site glomerular diseases registry,
Role: PI,
LLU Dept. of Medicine,
(03/2021)
Status: Approved
Assessment of kidney disease in COVID-19 patients during hospitalization and post recovery,
Role: PI,
LLU Dept. of Medicine,
(02/2021)
Status: Approved
Personalized AI-Powered Education for Rare Glomerular Diseases and Polycystic Kidney Disease,
Role: PI,
LLU Dept. of Medicine,
(02/2025)
Status: Approved
Di-PKD: A Pilot Trial of a 12-Month Targeted Dietary Intervention on Cyst Progression in Patients with Autosomal Dominant Polycystic Kidney Disease,
Role: Investigator,
LLU Dept. of Medicine,
(02/2025)
Status: Approved
Gender and Socioeconomic Disparities in Cardiovascular Events Among Patients with Nephrotic Syndrome,
Role: PI,
LLU Dept. of Medicine,
(03/2025)
Status: Approved
Development and Validation of a Board-Style Nephrology Question Bank for GlomCon Online Glomerular Disease and PKD Fellowship Program and Loma Linda University Internal Medicine Residents,
Role: PI,
LLU Dept. of Medicine,
(03/2026)
Status: Approved
Loma Linda Polycystic Kidney Disease Registry,
Role: PI,
LLU Dept. of Medicine,
(09/2025)
Status: Approved
Evaluating how Genetic Testing Influences Clinical Decision Making Among Nephrologists,
Role: PI,
LLU Dept. of Medicine,
(08/2026)
Status: Approved
Non-Profit Organization
Online Glomerular Diseases Fellowship Program,
Role: PD/PI,
American Society of Nephrology,
(07/2024 - 10/2026)
Status: Awarded